Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Published on October 15, 2009 at 12:35 AM · No Comments

Cardium Therapeutics (NYSE Amex: CXM) today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform. The study evaluated patients treated with the Excellarate product candidate (GAM501, which is a combination of Ad5PDGF-B and 2.6% collagen) or 2.6% collagen alone (matrix), compared to patients who received only the protocol-specified standard of care without any applied Ad5PDGF-B or collagen matrix. The Company will hold a webcast and conference call to discuss the clinical results of the Excellarate Matrix Phase 2b clinical study today, October 14, 2009, at 5:00 p.m. ET (access information is provided below).

Continued on Next page >>

Top-line results from Lymphoseek NEO3-09 Phase 3 study in breast cancer, melanomaNeoprobe Corporation, a diversified developer of innovative oncology diagnostic products, today anno...
Medtronic acquires chitosan-dextran gel technology for use in functional endoscopic sinus surgeryMedtronic, Inc. today announced that it has completed the purchase of rights to a chitosan-dextran g...
Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpointGenentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Av...
EHSI examines business plans and product lines of OceanBASISEmerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biot...
Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's diseaseThe Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $228...
Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual MeetingSangamo BioSciences, Inc. announced today that data from research and preclinical programs focused o...
Paralysis from a stroke: Rare nerve transfer improves mobilityThe Plastic Surgery Center today announced the successful results of a rare nerve transfer performed...
Why only some former smokers develop lung cancerCanadian researchers are trying to answer why some smokers develop lung cancer while others remain d...
Cheap drug combo stops breast cancer in its tracksA drug 'combo' of chemotherapy and a treatment for brittle bones has a dramatic effect on breast can...
Lungs' mast cells could provide new treatment target for asthma, other respiratory diseaseAn enzyme released by mast cells in the lungs appears to play a key role in the tightening of airway...
Obese women 3.5 times more likely to require a CaesareanLiverpool scientists have uncovered the reason why overweight women have more Caesarean sections; th...
Role of toxins in inherited diseaseA disease you are suffering today could be a result of your great-grandmother being exposed to an en...
Discovery of the enzyme that destroys cartilage in inflammatory arthritisA Melbourne-led team of scientists has discovered the enzyme that destroys cartilage in inflammatory...
Women delay AIDS with vitamins B, C and EDaily intake of multivitamins appears to delay the progress of the AIDS virus according to the resul...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.